医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Natco Pharma Limited Completes Transition of DASH Pharmaceuticals into Natco Pharma USA, Furthering Strategic Presence in the United States

2024年01月02日 PM10:00
このエントリーをはてなブックマークに追加


 

PARSIPPANY, N.J.

Natco Pharma Limited, a research and development (R&D)-focused pharmaceutical company based in India, today announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma. As of January 2, all products marketed by the company will transition to the Natco Pharma USA label, with no changes to the current NDC Numbers.

Natco Pharma USA is led by Subba Rao Mente, Chief Executive Officer. Julie Trendowicz and Nick DiMaio, the former Executive Vice President and President of DASH, respectively, will assume the same roles under Natco Pharma USA.

“By acquiring DASH, Natco Pharma has gained a strategic presence in the United States, connecting us directly with our valued customers in this crucial market,” said Subba Rao Mente, Chief Executive Officer of Natco Pharma USA. “This strategic move isn’t just about growth; it’s about bolstering our commitment to the U.S. pharmaceutical landscape.”

Since 2007, Natco Pharma has been active in the US market, forging co-development and licensing partnerships with leading U.S. generic pharmaceutical companies. The company’s collaborative efforts have culminated in the successful development and launch of a range of first-to-market generics and complex formulations, including Lenalidomide Capsules, Glatiramer Acetate Pre-Filled Syringes, Liposomal Doxorubicin Vials, Oseltamivir Phosphate Capsules, Lanthanum Carbonate Chewable Tablets, Everolimus Tablets, and Lapatinib Tablets. These launches have firmly established Natco Pharma as a formidable and trustworthy entity in the U.S. generic pharmaceutical industry, laying the groundwork for a large-scale expansion into the U.S. With the establishment of Natco Pharma USA, the company hopes to continue to increase accessibility and affordability of its generic products.

About Natco Pharma Limited

Natco Pharma Limited (Natco Pharma) is an R&D-focused pharmaceutical company based in Hyderabad, India, with subsidiaries in North America, Latin America, Australia, and Southeast Asia. With nearly 4,500 employees worldwide, the company develops, manufactures, and markets Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs) with a focus on niche therapeutic areas and complex products.

The company’s products reach more than 40 countries globally through its own subsidiaries and partnerships, where Natco products are out-licensed to multinational companies and companies with strong local and regional presence in their respective geographies.

About Natco Pharma USA

Based in New Jersey, Natco Pharma USA is the U.S. Sales and Marketing company for all DASH products, as well as current, future and non-committed products developed and manufactured by Natco Pharma. The company’s growing product catalog includes products across multiple therapeutic areas. Natco Pharma USA has various opportunities for collaborating, including a variety of profit-share and supply-chain initiatives such as Co-Development/Co-Ownership of ANDAs, Licensing of ANDAs, Acquisition of NDAs/ANDAs, and Authorized Generics. For more information, please visit www.natcopharmausa.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240102333961/en/

CONTACT

Laurel Hood

Health+Commerce

laurel@healthandcommerce.com

218-341-7270

同じカテゴリーの記事 

  • Kirin Holdings开始要约收购FANCL以使其成为全资子公司
  • Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
  • Kirin Holdings Commences Tender Offer To Make FANCL A Wholly-Owned Subsidiary
  • Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress
  • セルトリオン、EULAR 2024にて、関節リウマチ(RA)患者向けACTEMRA/RoActemra(トシリズマブ)のバイオシミラー候補であるCT-P47の第III相試験の有望な結果を示す